PTC Therapeutics, Inc. (PTCT)
PTC Therapeutics (PTCT) Upgraded to Strong Buy: Here's What You Should Know
PTC Therapeutics (PTCT) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
PTC Therapeutics (PTCT) Moves 7.2% Higher: Will This Strength Last?
PTC Therapeutics (PTCT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
PTC Therapeutics, Inc. (PTCT) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
PTC Therapeutics, Inc. (PTCT) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
PTC Therapeutics, Inc. (PTCT) Presents at Bank of America Global Healthcare Conference 2026 Transcript
PTC Therapeutics, Inc. (PTCT) Presents at Bank of America Global Healthcare Conference 2026 Transcript
PTC Therapeutics, Inc. (PTCT) Q1 2026 Earnings Call Transcript
PTC Therapeutics, Inc. (PTCT) Q1 2026 Earnings Call Transcript
Compared to Estimates, PTC Therapeutics (PTCT) Q1 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for PTC Therapeutics (PTCT) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
PTC Therapeutics (PTCT) Reports Q1 Loss, Tops Revenue Estimates
PTC Therapeutics (PTCT) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.45. This compares to earnings of $10.04 per share a year ago.
Exploring Analyst Estimates for PTC Therapeutics (PTCT) Q1 Earnings, Beyond Revenue and EPS
Looking beyond Wall Street's top-and-bottom-line estimate forecasts for PTC Therapeutics (PTCT), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended March 2026.
PTC Therapeutics (PTCT) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
PTC Therapeutics (PTCT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
PTC Therapeutics, Inc. (PTCT) Discusses 24-Month Interim Results of PIVOT-HD Long-Term Extension Study of Votoplam in Huntington's Disease Transcript
PTC Therapeutics, Inc. (PTCT) Discusses 24-Month Interim Results of PIVOT-HD Long-Term Extension Study of Votoplam in Huntington's Disease Transcript
Abacus FCF Advisors LLC Makes New $5.76 Million Investment in PTC Therapeutics, Inc. $PTCT
Abacus FCF Advisors LLC bought a new stake in PTC Therapeutics, Inc. (NASDAQ: PTCT) in the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor bought 75,757 shares of the biopharmaceutical company's stock, valued at approximately $5,755,000. Abacus FCF Advisors LLC owned about 0.09% of
Cinctive Capital Management LP Takes Position in PTC Therapeutics, Inc. $PTCT
Cinctive Capital Management LP purchased a new position in PTC Therapeutics, Inc. (NASDAQ: PTCT) in the undefined quarter, according to the company in its most recent disclosure with the SEC. The fund purchased 95,308 shares of the biopharmaceutical company's stock, valued at approximately $5,849,000. Cinctive Capital Management LP owned about 0.12% of PTC
